LC3B has been identified as a potential biomarker and high LC3B rates can predict poor prognosis in hepatocellular carcinoma as well as colon cancer and TNBC, while p62 has also been used as a biomarker for colon cancer (240–242). Here, MAP1LC3B is linked to malignant colon neoplasm.